All In Biotech

Drug Trial Radar · NCT00436553

Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization

A 24-month Randomized, Double-masked, Controlled, Multicenter, Phase IIIB Study Assessing Safety and Efficacy of Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab Versus Ranibizumab Monotherapy in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration

Last checked: Nov 19, 2026Latest source record: Apr 19, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 321 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

321

Actual

Start

Feb 2007

Primary completion

Oct 2009

Study completion Oct 2009

Sponsor

Lead sponsor
NovartisNovartis (NVS)
Sponsor type
Industry
First posted
Feb 19, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluated the effect of combination therapy with verteporfin photodynamic therapy and ranibizumab on visual acuity and anatomic outcomes compared to ranibizumab monotherapy and the durability of response observed in patients with choroidal neovascularization secondary to age-related macular degeneration.

Conditions

  • Macular Degeneration
  • Choroidal Neovascularization

Interventions

  • Verteporfin Photodynamic TherapyDrug

    After a 10-minute intravenous infusion of verteporfin at a dose of 6 mg/m\^2 body surface area, verteporfin was activated by light application of 50 J/cm\^2 (Standard Fluence rate) or 25 J/cm\^2 (Reduced Fluence rate) to the study eye, begun 15 minutes after the start of the infusion.

  • RanibizumabDrug

    Ranibizumab 0.5 mg administered as an intravitreal injection.

  • Verteporfin PlaceboDrug

    To maintain masking, as a placebo for verteporfin photodynamic therapy, patients were administered a 10-minute intravenous infusion of 5% dextrose solution, followed by light application of 50 J/cm\^2 to the study eye, begun 15 minutes after the start of infusion.

  • Ranibizumab PlaceboDrug

    To maintain masking, patients in the combination groups received sham intravitreal injections whenever retreatment with active Ranibizumab was not warranted based on the retreatment algorithm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change From Baseline in Best-corrected Visual Acuity (BCVA) of the Study Eye at Month 12Time frame: Baseline and Month 12
  2. Percent of Patients With a Treatment-free Interval of at Least 3 Months Following the Month 2 VisitTime frame: Month 2 up to Month 11

Locations

43 sites in 2 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Tucson, Arizona

  • Novartis Investigative Site

    Beverly Hills, California

  • Novartis Investigative Site

    Oakland, California

  • Novartis Investigative Site

    Pasadena, California

  • Novartis Investigative Site

    Sacramento, California

  • West Coast Retina Medical Group Inc. - 185 Berry St. Suite 130

    San Francisco, California

  • Novartis Investigative Site

    Santa Ana, California

  • Novartis Investigative Site

    Denver, Colorado

  • Novartis Investigative Site

    ‘Aiea, Hawaii

  • Novartis Investigative Site

    Iowa City, Iowa

  • Novartis Investigative Site

    Wichita, Kansas

  • Novartis Investigative Site

    Lexington, Kentucky

  • Novartis Investigative Site

    Paducah, Kentucky

  • Novartis Investigative Site

    Baltimore, Maryland

  • Novartis Investigative Site

    Grand Rapids, Michigan

  • Novartis Investigative SIte

    Royal Oak, Michigan

  • Novartis Investigative Site

    Williamsburg, Michigan

  • Novartis Investigative Site

    Independence, Missouri

  • Novartis Investigative Site

    St Louis, Missouri

  • Novartis Investigative Site

    Toms River, New Jersey

  • Novartis Investigative Site

    Lynbrook, New York

  • Novartis Investigative Site

    Rochester, New York

  • Novartis Investigative Site

    Beachwood, Ohio

  • Novartis Investigative Site

    Cincinnati, Ohio

  • Novartis Investigative Site

    Cleveland, Ohio

  • Novartis Investigative Site

    Pittsburgh, Pennsylvania

  • Novartis Investigative Site

    West Mifflin, Pennsylvania

  • Novartis Investigative Site

    West Columbia, South Carolina

  • Novartis Investigative Site

    Rapid City, South Dakota

  • Novartis Investigative Site

    Kingsport, Tennessee

  • Novartis Investigative Site

    Knoxville, Tennessee

  • Novartis Investigative Site

    Austin, Texas

  • Novartis Investigative Site

    Houston, Texas

  • Novartis Investigative Site

    Fairfax, Virginia

  • Novartis Investigative Site

    Richmond, Virginia

  • Novartis Investigative Site

    Milwaukee, Wisconsin

  • Novartis Investigative Site

    Edmonton, Alberta, Canada

  • Novartis Investigative Site

    Vancouver, British Columbia, Canada

  • Novartis Investigative Site

    Halifax, Nova Scotia, Canada

  • Ivey Eye Institute, Dr. Thomas Sheidow

    London, Ontario, Canada

Showing 40 of 43 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.